P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
Authors: S. de Botton, S. Choe, D. Marchione, P. Montesinos, C. Recher, S. Vives Polo, E. Zarzycka, J. Wang, G. Bertani, M. Heuser, R. Calado, A. Schuh, S.-P. Yeh, J. Hui, S. Pandya, D. Gianolio, S. Daigle, C. DiNardo, H. Dohner
Journal: HemaSphere (2022)

Background: Acute myeloid leukemia (AML) is a disease with a dynamic mutational landscape; 6–10% of patients (pts) have somatic mutations in isocitrate dehydrogenase 1 (IDH1), which can drive oncogenesis. Ivosidenib (IVO) is a potent oral targeted inhibitor of mutant IDH1 (mIDH1). IVO 500 mg QD + azacitidine (AZA) 75 mg/m2 SC or IV for 7 days in 28-day cycles was shown to significantly improve event-free survival (HR=0.33 [95% CI 0.16, 0.69], p=0.0011), median overall survival (24.0 vs 7.9 months), and complete remission + partial hematologic recovery rates (CR/CRh; 52.8% vs 17.6%) vs placebo + AZA in the double-blind phase 3 AGILE study (NCT03173248) in pts with newly diagnosed IDH1-mutated AML (ND-AML). Aims: To assess the impact of IVO+AZA on IDH1-mutation clearance (IDH1-MC) and baseline co-mutation analysis from AGILE. Methods: Genomic DNA from bone marrow mononuclear cells (BMMCs) or peripheral blood mononuclear cells (PBMCs), and/or bone marrow aspirate (BMA) were used for molecular studies. IDH1-MC analysis on BMMCs was performed by BEAMing digital PCR (limit of detection 0.02%-0.04%). BMA, BMMCs and PBMCs were utilized for co-mutational analysis by next-generation sequencing, ACE Extended Cancer Panel (detection limit 2%). All patients gave written informed consent. Results: 146 pts were randomized: 72 to IVO+AZA; 74 to placebo+AZA. Median (range) baseline mIDH1 variant allele frequency in BMMCs was 36.7% (3.1–50.5%) in the IVO+AZA arm and 35.5% (3.0–48.6%) in the placebo+AZA arm. Updated IDH1-MC data (October 2021) from 47 IVO+AZA and 32 placebo+AZA treated pts with at least 1 on-treatment sample demonstrated IDH1-MC in 21/35 (60%) IVO+AZA pts achieving CR/CRh vs 4/11 (36%) placebo+AZA pts. In CR/CRh pts with time points available after IDH1-MC, suppression of the mIDH1 was durable and IDH1-MC maintained in all subsequent samples in 17/17 (100%) IVO+AZA treated pts and 1/3 (33%) placebo+AZA pts. Further analysis of baseline co-mutations on 120 pts (IVO+AZA: n=58; placebo+AZA: n=62) showed that DNMT3A, SRSF2, and RUNX1 were the most frequent in both treatment arms. Importantly, comparison of CR/CRh and non CR/CRh responses by cohort did not identify any single gene or pathway associated with an inferior outcome in IVO+AZA pts compared to placebo+AZA pts (p<0.05, Fisher’s Exact test). Several genes (DNMT3A, RUNX1, SRSF2, STAG2) and pathways (Differentiation, Epigenetics, Splicing) were associated with improved outcomes with IVO+AZA, including the RTK pathway, which was previously reported to be associated with primary resistance to IVO monotherapy. Further analysis of patient subgroups, including R132 variants (i.e., R132C vs R132S), will be presented. Summary/Conclusion: These data suggest that improved clinical outcomes with IVO+AZA are associated with sustained clearance of the mIDH1 clone including pts with disease that harbor mutations implicated in resistance to IVO monotherapy (e.g., with RTK pathway mutations).